Comparing serum concentration of spexin among patients with metabolic syndrome, healthy overweight/obese, and normal-weight individuals
- PMID: 31696087
- PMCID: PMC6825375
- DOI: 10.34171/mjiri.33.93
Comparing serum concentration of spexin among patients with metabolic syndrome, healthy overweight/obese, and normal-weight individuals
Abstract
Background: There are many factors related to etiology of metabolic syndrome (MetS) including obesity. Spexin, a peptide hormone released from adipose tissue, is the most down-regulated gene in obese, compared to non-obese adipose tissue. Hence, it potentially contributes to the progression and development of metabolic diseases. This study was designed to evaluate serum concentration of spexin in patients with MetS compared to weight-matched and normal-weight controls. Methods: In this case-control study, 153 participants (51 per group) were collected from October 2014 to June 2016. The study groups were all matched for age and sex and included overweight/obese individuals with MetS and 2 control groups without MetS (including weight-matched and normal-weight participants). Body composition and serum concentration of spexin and leptin were measured. Results: Serum leptin and spexin levels were significantly higher and lower, respectively, in normal-weight compared to overweight/obese groups with/without MetS (p< 0.02). No significant difference was observed in serum leptin and spexin concentrations between the overweight/obese groups with/without MetS (p≥ 0.05). Also, spexin, with cutoff value of 4.6, had 78% sensitivity and 82% specificity for diagnosing overweight/obese from normal-weight participants. Spexin had 78% sensitivity and specificity, with cutoff value of 4.35, in diagnosing MetS participants from normal-weight group. Conclusion: This study found no correlation between the circulating level of spexin and MetS development. Higher serum concentration of spexin in normal-weight adults compared to the obese participants illustrated the potential role of this novel peptide in obesity.
Keywords: Leptin; Metabolic syndrome; Obesity; Spexin.
© 2019 Iran University of Medical Sciences.
Similar articles
-
Metabolic Syndrome Patients Have Lower Levels of Adropin When Compared With Healthy Overweight/Obese and Lean Subjects.Am J Mens Health. 2017 Mar;11(2):426-434. doi: 10.1177/1557988316664074. Epub 2016 Aug 22. Am J Mens Health. 2017. PMID: 27550773 Free PMC article.
-
Decreased Circulating Levels of Spexin in Obese Children.J Clin Endocrinol Metab. 2016 Jul;101(7):2931-6. doi: 10.1210/jc.2016-1177. Epub 2016 May 24. J Clin Endocrinol Metab. 2016. PMID: 27218269 Free PMC article.
-
Different spexin level in obese vs normal weight children and its relationship with obesity related risk factors.Nutr Metab Cardiovasc Dis. 2020 Apr 12;30(4):674-682. doi: 10.1016/j.numecd.2019.11.008. Epub 2019 Nov 23. Nutr Metab Cardiovasc Dis. 2020. PMID: 32139252
-
Emerging central and peripheral actions of spexin in feeding behavior, leptin resistance and obesity.Biochem Pharmacol. 2022 Aug;202:115121. doi: 10.1016/j.bcp.2022.115121. Epub 2022 Jun 6. Biochem Pharmacol. 2022. PMID: 35679893 Review.
-
Adipose tissue spexin in physical exercise and age-associated diseases.Ageing Res Rev. 2022 Jan;73:101509. doi: 10.1016/j.arr.2021.101509. Epub 2021 Nov 6. Ageing Res Rev. 2022. PMID: 34752956 Review.
Cited by
-
Circulating Spexin Is Associated with Body Mass Index and Fat Mass but Not with Physical Activity and Psychological Parameters in Women across a Broad Body Weight Spectrum.J Clin Med. 2022 Aug 30;11(17):5107. doi: 10.3390/jcm11175107. J Clin Med. 2022. PMID: 36079049 Free PMC article.
-
Impact of spexin on metabolic diseases and inflammation: An updated minireview.Exp Biol Med (Maywood). 2022 Apr;247(7):567-573. doi: 10.1177/15353702211072443. Epub 2022 Jan 22. Exp Biol Med (Maywood). 2022. PMID: 35068225 Free PMC article. Review.
-
Cord Blood Levels of Spexin, Leptin, and Visfatin in Term Infants Born Small, Appropriate, and Large for Gestational Age and Their Association with Newborn Anthropometric Measurements.J Clin Res Pediatr Endocrinol. 2022 Dec 1;14(4):444-452. doi: 10.4274/jcrpe.galenos.2022.2022-4-24. Epub 2022 Jul 21. J Clin Res Pediatr Endocrinol. 2022. PMID: 35859814 Free PMC article.
-
Spexin Regulates Hypothalamic Leptin Action on Feeding Behavior.Biomolecules. 2022 Jan 31;12(2):236. doi: 10.3390/biom12020236. Biomolecules. 2022. PMID: 35204737 Free PMC article.
-
The Association of Serum Circulating Neuropeptide Q and Chemerin Levels with Cardiometabolic Risk Factors among Patients with Metabolic Syndrome.Biomolecules. 2021 Dec 10;11(12):1863. doi: 10.3390/biom11121863. Biomolecules. 2021. PMID: 34944507 Free PMC article.
References
-
- Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA. et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5. - PubMed
-
- Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J. et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288(21):2709–16. - PubMed
-
- Lorenzo C, Williams K, Hunt KJ, Haffner SM. Trend in the prevalence of the metabolic syndrome and its impact on cardiovascular disease incidence: the San Antonio Heart Study. Diabetes Care. 2006;29(3):625–30. - PubMed
-
- Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52(5):1210–4. - PubMed
LinkOut - more resources
Full Text Sources